Gild analyst ratings
WebApr 14, 2024 · Gilead Sciences (NASDAQ:GILD – Get Rating) had its target price increased by equities researchers at Morgan Stanley from $81.00 to $85.00 in a research report issued to clients and investors on Wednesday, The Fly reports.The firm presently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s … WebGilead Sciences Inc. analyst ratings, historical stock prices, earnings estimates & actuals. GILD.IT updated stock price target summary.
Gild analyst ratings
Did you know?
Web5 rows · See Gilead Sciences, Inc. (GILD) stock analyst estimates, including earnings and revenue, EPS, ... Web1 day ago · Gilead Sciences will be looking to display strength as it nears its next earnings release. On that day, Gilead Sciences is projected to report earnings of $1.62 per share, which would represent a ...
WebApr 10, 2024 · GILD Complete Gilead Sciences Inc. stock news by MarketWatch. ... RBC Capital Sticks to Its Hold Rating for Gilead Sciences (GILD) Apr. 7, 2024 at 9:45 p.m. ET ... Analysts Eye InflaRx COVID-19 ... WebApr 14, 2024 · Gilead Sciences (NASDAQ:GILD – Get Rating) had its target price increased by equities researchers at Morgan Stanley from $81.00 to $85.00 in a …
Web4 hours ago · Gilead Sciences Inc. research and ratings by Barron's. View GILD revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. Web2 days ago · Get the latest Gilead Sciences, Inc GILD detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... any analyst opinion/rating/report or any …
WebAnalyst Ratings are available for US and Canadian equities. Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock.
WebApr 6, 2024 · The Gilead Sciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd … tara deanWebApr 12, 2024 · Analyst Rating Coverage. Morgan Stanley & Co(Rank#1), has maintained its Equal-Weight rating on Gilead Sciences, a biopharmaceutical company known for its innovative treatments for HIV, liver diseases, and other conditions.Morgan Stanley also raised its target price on Gilead Sciences from USD 81 to USD 85. months. taradejkaWebApr 6, 2024 · Get Wall Street analysts ratings for Gilead Sciences, Inc. (GILD). Buy or Sell this stock? See what the analysts say. tara demarsWebApr 6, 2024 · The 53 analysts offering price forecasts for Gilead Sciences have a median target of 78.19, with a high estimate of 112.00 and a low estimate of 56.00. ... Analyst Rating Price 03/06/23 RBC ... taradejka wikipediaWebJan 6, 2024 · Gilead Sciences (NASDAQ:GILD) has observed the following analyst ratings within the last quarter: In the last 3 months, 5 analysts have offered 12-month price targets for Gilead Sciences. The ... tara delamarterWeb1 day ago · Analysts have provided the following ratings for Gilead Sciences (NASDAQ:GILD) within the last quarter: According to 9 analyst offering 12-month price targets in the last 3 months, Gilead Sciences ... tara demasi hillsborough njWebApr 11, 2024 · According to 35 stock analysts, the average 12-month stock price forecast for GILD stock is $90.74, which predicts an increase of 9.93%. The lowest target is $63.63 and the highest is $120.75. On average, analysts rate GILD stock as a buy. tara demarzian